JP2018504145A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504145A5 JP2018504145A5 JP2017557491A JP2017557491A JP2018504145A5 JP 2018504145 A5 JP2018504145 A5 JP 2018504145A5 JP 2017557491 A JP2017557491 A JP 2017557491A JP 2017557491 A JP2017557491 A JP 2017557491A JP 2018504145 A5 JP2018504145 A5 JP 2018504145A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- tcr
- domain
- dck
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091008874 T cell receptors Proteins 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 13
- 108010033174 Deoxycytidine kinase Proteins 0.000 claims 6
- 102100029588 Deoxycytidine kinase Human genes 0.000 claims 6
- 210000002865 immune cell Anatomy 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 238000010322 bone marrow transplantation Methods 0.000 claims 2
- 208000030963 borderline personality disease Diseases 0.000 claims 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 108020001756 ligand binding domains Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 101000917383 Homo sapiens Deoxycytidine kinase Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201570044 | 2015-01-26 | ||
| DKPA201570044 | 2015-01-26 | ||
| EPPCT/EP2015/055848 | 2015-03-19 | ||
| PCT/EP2015/055848 WO2015140268A1 (en) | 2014-03-19 | 2015-03-19 | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
| PCT/EP2016/051471 WO2016120220A1 (en) | 2015-01-26 | 2016-01-25 | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018504145A JP2018504145A (ja) | 2018-02-15 |
| JP2018504145A5 true JP2018504145A5 (cg-RX-API-DMAC7.html) | 2019-03-07 |
Family
ID=52396337
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557487A Active JP6884709B2 (ja) | 2015-01-26 | 2016-01-25 | 操作された免疫細胞の選別／枯渇のための、ｍＡｂが推進するキメラ抗原受容体系 |
| JP2017557490A Withdrawn JP2018504144A (ja) | 2015-01-26 | 2016-01-25 | Ｃｌｌ１特異的多鎖キメラ抗原受容体 |
| JP2017557489A Active JP6779909B2 (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ＣＬＬ１特異的単鎖キメラ抗原受容体（ｓｃＣＡＲ） |
| JP2017557488A Pending JP2018504143A (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ｈｓｐ７０特異的キメラ抗原受容体（ｃａｒ） |
| JP2017557491A Pending JP2018504145A (ja) | 2015-01-26 | 2016-01-25 | 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557487A Active JP6884709B2 (ja) | 2015-01-26 | 2016-01-25 | 操作された免疫細胞の選別／枯渇のための、ｍＡｂが推進するキメラ抗原受容体系 |
| JP2017557490A Withdrawn JP2018504144A (ja) | 2015-01-26 | 2016-01-25 | Ｃｌｌ１特異的多鎖キメラ抗原受容体 |
| JP2017557489A Active JP6779909B2 (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ＣＬＬ１特異的単鎖キメラ抗原受容体（ｓｃＣＡＲ） |
| JP2017557488A Pending JP2018504143A (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ｈｓｐ７０特異的キメラ抗原受容体（ｃａｒ） |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20180002427A1 (cg-RX-API-DMAC7.html) |
| EP (5) | EP3250602A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6884709B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20170135824A (cg-RX-API-DMAC7.html) |
| CN (5) | CN107406516B (cg-RX-API-DMAC7.html) |
| AU (5) | AU2016212160B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112017015453A2 (cg-RX-API-DMAC7.html) |
| CA (4) | CA2973529A1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK3250604T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2869972T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL252937B (cg-RX-API-DMAC7.html) |
| MX (3) | MX381908B (cg-RX-API-DMAC7.html) |
| RU (3) | RU2732925C2 (cg-RX-API-DMAC7.html) |
| WO (5) | WO2016120216A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| MX370272B (es) * | 2014-03-19 | 2019-12-09 | Cellectis | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. |
| SG11201707089WA (en) | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| AU2016307050A1 (en) * | 2015-08-11 | 2018-02-15 | Cellectis | Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation |
| CN108472365A (zh) | 2015-10-30 | 2018-08-31 | 艾丽塔生物治疗剂公司 | 用于肿瘤转导的组合物和方法 |
| CA3002674A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| CN105331586B (zh) * | 2015-11-20 | 2020-09-15 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
| CN108290955A (zh) * | 2015-11-24 | 2018-07-17 | 塞勒兰特治疗公司 | 人源化抗-cll-1抗体 |
| CN108699557B (zh) | 2015-12-04 | 2025-08-15 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| ES2962588T3 (es) * | 2016-03-23 | 2024-03-20 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Proteínas de fusión de PD-1 y 4-1BB |
| EP3439699A4 (en) | 2016-04-04 | 2019-11-20 | Hemogenyx LLC | METHOD FOR ELIMINATING HEMATOPOETIC STEM CELLS / HEMATOPOIDIC PRECURSOR CELLS (HSC / HP) IN A PATIENT WITH BI-SPECIFIC ANTIBODIES |
| US11104738B2 (en) | 2016-04-04 | 2021-08-31 | Hemogenyx Pharmaceuticals Llc | Monoclonal antibodies to human FLT3/FLK2 receptor protein |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CN118652336A (zh) | 2016-06-08 | 2024-09-17 | 普瑞赛格恩公司 | Cd33特异性嵌合抗原受体 |
| US11466291B2 (en) | 2016-07-06 | 2022-10-11 | Cellectis | Sequential gene editing in primary immune cells |
| CA3034324A1 (en) * | 2016-08-19 | 2018-02-22 | Janssen Biotech, Inc. | Methods of treating crohn's disease with an anti-nkg2d antibody |
| WO2018057915A1 (en) | 2016-09-23 | 2018-03-29 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| ES2811500T3 (es) | 2016-10-04 | 2021-03-12 | Prec Biosciences Inc | Dominios coestimuladores para su uso en células genéticamente modificadas |
| KR20190127655A (ko) | 2016-10-19 | 2019-11-13 | 프로디자인 소닉스, 인크. | 음향학에 의한 친화성 세포 추출 |
| WO2018073394A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| IL266892B2 (en) | 2016-12-02 | 2025-10-01 | Univ Southern California | Artificial immune receptors and methods of using them |
| WO2018115189A1 (en) | 2016-12-21 | 2018-06-28 | Cellectis | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy |
| US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| CA3061898A1 (en) | 2016-12-28 | 2019-10-29 | Green Cross Lab Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| CN108250301A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多靶点嵌合抗原受体 |
| US11975029B2 (en) | 2017-02-28 | 2024-05-07 | Vor Biopharma Inc. | Compositions and methods for inhibition of lineage specific proteins |
| CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| JP7205995B2 (ja) * | 2017-03-29 | 2023-01-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子 |
| WO2018178377A1 (en) | 2017-03-31 | 2018-10-04 | Cellectis Sa | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| JP6748221B2 (ja) | 2017-04-01 | 2020-08-26 | エーブイエム・バイオテクノロジー・エルエルシー | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| CA3062328A1 (en) | 2017-06-02 | 2018-12-06 | Pfizer Inc. | Chimeric antigen receptors targeting flt3 |
| WO2018226897A1 (en) | 2017-06-07 | 2018-12-13 | Intrexon Corporation | Expression of novel cell tags |
| US12275787B2 (en) * | 2017-06-21 | 2025-04-15 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (CARs), compositions and methods thereof |
| CA3067914A1 (en) | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| BR112020001207A2 (pt) | 2017-07-20 | 2020-09-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | composições e métodos para atingir cânceres expressando cd33 |
| WO2019016360A1 (en) | 2017-07-21 | 2019-01-24 | Cellectis | MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT |
| CN118206655A (zh) * | 2017-07-25 | 2024-06-18 | 得克萨斯大学体系董事会 | 增强的嵌合抗原受体及其用途 |
| WO2019020733A1 (en) | 2017-07-26 | 2019-01-31 | Cellectis | METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR) |
| EA202090839A1 (ru) * | 2017-09-27 | 2021-02-04 | Юниверсити Оф Саутерн Калифорния | Новые платформы для костимуляции, новые конструкции car и другие улучшения для адаптивной клеточной терапии |
| WO2019072824A1 (en) | 2017-10-09 | 2019-04-18 | Cellectis | IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109837303A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| CN109836496A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向cd317的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| WO2019106163A1 (en) | 2017-12-01 | 2019-06-06 | Cellectis | Reprogramming of genetically engineered primary immune cells |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| WO2019129851A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
| CN109608548A (zh) * | 2017-12-29 | 2019-04-12 | 郑州大学第附属医院 | 基于人源cd20抗体的嵌合抗原受体、慢病毒表达载体及其应用 |
| US20210061879A1 (en) * | 2017-12-29 | 2021-03-04 | City Of Hope | Meditope-enabled t cells |
| WO2019129850A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| US11951129B2 (en) | 2018-01-09 | 2024-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CLEC12A-expressing cancers |
| TW201936633A (zh) | 2018-02-01 | 2019-09-16 | 美商輝瑞大藥廠 | 標靶至cd70的嵌合抗原受體 |
| WO2019152705A1 (en) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Antibodies specific for cd70 and their uses |
| WO2019169290A1 (en) | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| KR20200131867A (ko) * | 2018-03-14 | 2020-11-24 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 항-cd33 키메라 항원 수용체 및 이의 용도 |
| WO2019183362A1 (en) * | 2018-03-21 | 2019-09-26 | Dana-Farber Cancer Institute, Inc. | Fc variant compositions and methods of use thereof |
| CN108530536B (zh) * | 2018-03-27 | 2021-08-13 | 刘爽 | Cart-cd123及其制备与应用 |
| CN108531457A (zh) * | 2018-04-10 | 2018-09-14 | 杭州荣泽生物科技有限公司 | 一种Cas9/RNP敲除T细胞PD-1和LAG3基因及制备CAR-T细胞的方法 |
| MX2020010808A (es) | 2018-04-13 | 2021-03-02 | Sangamo Therapeutics France | Receptor de antigeno quimerico especifico para el receptor de interleucina-23. |
| PE20210666A1 (es) | 2018-05-11 | 2021-03-31 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer |
| US12054558B2 (en) | 2018-05-23 | 2024-08-06 | The Jackson Laboratory | Anti-NGly-1 antibodies and methods of use |
| WO2019233842A1 (en) | 2018-06-08 | 2019-12-12 | F. Hoffmann-La Roche Ag | Peptidic linker with reduced post-translational modification |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2019246593A2 (en) * | 2018-06-22 | 2019-12-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders |
| US20210268028A1 (en) * | 2018-07-02 | 2021-09-02 | Cellectis | Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml |
| WO2020033585A1 (en) * | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Methods for combinatorial screening and use of therapeutic targets thereof |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| CN113423725A (zh) | 2018-08-28 | 2021-09-21 | Vor生物制药股份有限公司 | 遗传工程化造血干细胞及其用途 |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR20210089179A (ko) * | 2018-10-26 | 2021-07-15 | 카파 테라퓨틱스 리미티드 | Cll1을 표적으로 하는 항체 및 이의 응용 |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| KR20210099574A (ko) | 2018-12-01 | 2021-08-12 | 알로젠 테라퓨틱스 인코포레이티드 | B-세포 성숙화 항원을 표적화하는 키메라 항원 수용체 및 이의 사용 방법 |
| KR20210111785A (ko) | 2018-12-18 | 2021-09-13 | 베링거 잉겔하임 아이오 캐나다 인크. | Flt3 항진제 항체 및 이의 용도 |
| CN113543799B (zh) | 2019-03-01 | 2024-08-02 | 艾洛基治疗公司 | 靶向dll3的嵌合抗原受体和结合剂 |
| AU2020232597B2 (en) | 2019-03-01 | 2025-08-07 | Allogene Therapeutics, Inc. | Constitutively active chimeric cytokine receptors |
| JP7633937B2 (ja) | 2019-03-01 | 2025-02-20 | アロジーン セラピューティクス，インコーポレイテッド | Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| EP3937974A1 (en) * | 2019-03-11 | 2022-01-19 | Leucid Bio Ltd | Muc1 parallel car (pcar) therapeutic agents |
| US20220152106A1 (en) * | 2019-03-15 | 2022-05-19 | Rutgers, The State University Of New Jersey | Cd147 chimeric antigen receptors and methods of use |
| KR20210144679A (ko) | 2019-03-21 | 2021-11-30 | 알로젠 테라퓨틱스 인코포레이티드 | TCRαβ+ 세포 고갈 효율을 향상시키는 방법 |
| EP3947471A4 (en) * | 2019-03-27 | 2023-03-15 | The Trustees of The University of Pennsylvania | TN-MUC1 CHIMERIC ANTIGEN RECEPTOR (CAR) T-LYMPHOCYTE THERAPY |
| WO2020210719A1 (en) | 2019-04-10 | 2020-10-15 | Elevatebio Management, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
| JP7664180B2 (ja) * | 2019-04-26 | 2025-04-17 | アロジーン セラピューティクス，インコーポレイテッド | リツキシマブ耐性キメラ抗原受容体およびその用途 |
| WO2020219812A1 (en) | 2019-04-26 | 2020-10-29 | Allogene Therapeutics, Inc. | Methods of manufacturing allogeneic car t cells |
| EA202192975A1 (ru) | 2019-04-30 | 2022-02-01 | Криспр Терапьютикс Аг | Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19 |
| CA3143108A1 (en) * | 2019-06-19 | 2020-12-24 | Julius-Maximilians-Universitat Wurzburg | Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
| CN112111013A (zh) * | 2019-06-22 | 2020-12-22 | 南京北恒生物科技有限公司 | 一种靶向claudin 18.2的通用型嵌合抗原受体T细胞、构建方法及其用途 |
| JP2022540602A (ja) * | 2019-07-09 | 2022-09-16 | ヘモジェニックス ファーマシューティカルズ リミテッド ライアビリティ カンパニー | 二重特異性抗体を使用して患者の造血幹細胞／造血前駆細胞（ｈｓｃ／ｈｐ）を除去する方法 |
| WO2021041806A1 (en) | 2019-08-30 | 2021-03-04 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| EP4038190A1 (en) | 2019-10-03 | 2022-08-10 | Artisan Development Labs, Inc. | Crispr systems with engineered dual guide nucleic acids |
| EP3808766A1 (en) | 2019-10-15 | 2021-04-21 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
| WO2021130250A1 (en) | 2019-12-23 | 2021-07-01 | Cellectis | New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy |
| CA3168433A1 (en) | 2020-01-16 | 2021-07-22 | Allogene Therapeutics, Inc. | Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors |
| CN115175929A (zh) | 2020-02-24 | 2022-10-11 | 艾洛基治疗公司 | 活性增强的bcma car-t细胞 |
| US20230085724A1 (en) | 2020-03-05 | 2023-03-23 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
| IL296176A (en) * | 2020-03-06 | 2022-11-01 | Purdue Research Foundation | Methods, compounds and compositions for altering car-t cell activity |
| BR112022018359A2 (pt) | 2020-03-16 | 2023-01-24 | Univ Southern California | Novos domínios de ligação ao antígeno e receptores de antígeno sintéticos incorporando os mesmos |
| WO2021188631A1 (en) * | 2020-03-18 | 2021-09-23 | Kindred Biosciences, Inc. | Anti-il4 receptor antibodies for veterinary use |
| JP2023518293A (ja) | 2020-03-20 | 2023-04-28 | ライル・イミュノファーマ，インコーポレイテッド | 新規の組換え細胞表面マーカー |
| EP4125946A4 (en) * | 2020-03-27 | 2024-04-24 | Board of Regents, The University of Texas System | Monoclonal antibodies targeting hsp70 and therapeutic uses thereof |
| AU2021268253A1 (en) | 2020-05-06 | 2022-12-08 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
| EP4148065A4 (en) * | 2020-05-08 | 2024-05-29 | SMT Bio Co., Ltd. | Chimeric antigen receptor for treatment of cancer |
| GB202007842D0 (en) * | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| CN113735973B (zh) * | 2020-05-28 | 2023-05-09 | 中国科学院微生物研究所 | 一种抗SIRPα抗体及其应用 |
| JP7760166B2 (ja) * | 2020-05-29 | 2025-10-27 | ブライトパス・バイオ株式会社 | 抗ｃｄ７３抗体およびその用途 |
| EP4176261A1 (en) | 2020-07-03 | 2023-05-10 | Cellectis S.A. | Method for determining potency of chimeric antigen receptor expressing immune cells |
| CN116194488A (zh) | 2020-07-21 | 2023-05-30 | 艾洛基治疗公司 | 具有增强的信号传导和活性的嵌合抗原受体和其用途 |
| US20230248825A1 (en) | 2020-07-24 | 2023-08-10 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
| CA3188431A1 (en) | 2020-08-07 | 2022-02-10 | Carsten LINNEMANN | Methods to enrich genetically engineered t cells |
| CN112079927B (zh) * | 2020-09-18 | 2021-12-28 | 西安桑尼赛尔生物医药有限公司 | 一种cd123结合蛋白、含其的car及其应用 |
| WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| CN113980134B (zh) * | 2020-12-11 | 2022-05-31 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113248622B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 一种靶向cll1和nkg2d配体的双靶点嵌合抗原受体及其应用 |
| JP2023553634A (ja) | 2020-12-14 | 2023-12-25 | アロジーン セラピューティクス，インコーポレイテッド | 治療用のｃａｒ ｔ細胞を特徴付けるための方法および試薬 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| IL303270A (en) | 2020-12-21 | 2023-07-01 | Allogene Therapeutics Inc | The CD45–GATE vehicle activates a protease |
| JP7623497B2 (ja) | 2020-12-31 | 2025-01-28 | サノフイ | ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ |
| CN112694532B (zh) * | 2021-01-12 | 2023-04-18 | 倍而达药业（苏州）有限公司 | 抗Siglec-15的抗体或其抗原结合片段及应用 |
| CN112661816B (zh) * | 2021-01-13 | 2022-10-11 | 江西省人民医院 | 用于利妥昔单抗血药浓度检测的人工抗原及试剂盒 |
| US12365873B2 (en) | 2021-01-28 | 2025-07-22 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| IL303853A (en) | 2021-01-29 | 2023-08-01 | Allogene Therapeutics Inc | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS |
| AU2022227650A1 (en) | 2021-02-25 | 2023-10-12 | Celyntra Therapeutics Sa | Compositions and methods for targeting, editing, or modifying genes |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| MX2023012760A (es) * | 2021-04-30 | 2023-11-13 | Cellectis Sa | Nuevos cars anti-muc1 y celulas inmunitarias editadas geneticamente para inmunoterapia contra el cancer de tumores solidos. |
| US20250179481A1 (en) | 2021-06-01 | 2025-06-05 | Celyntra Therapeutics Sa | Compositions and methods for targeting, editing, or modifying genes |
| WO2022266075A1 (en) | 2021-06-14 | 2022-12-22 | Caribou Biosciences, Inc. | Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain |
| WO2022266203A1 (en) | 2021-06-15 | 2022-12-22 | Allogene Therapeutics, Inc. | Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence |
| CN115477704B (zh) * | 2021-06-16 | 2024-02-23 | 四川大学华西医院 | 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用 |
| CN115477705B (zh) * | 2021-06-16 | 2024-02-23 | 四川大学华西医院 | 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用 |
| CA3223311A1 (en) | 2021-06-18 | 2022-12-22 | Andrea BARGHETTI | Compositions and methods for targeting, editing or modifying human genes |
| WO2023020471A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd123-targetting antibodies and uses thereof in cancer therapies |
| IL311128A (en) | 2021-09-01 | 2024-04-01 | Springworks Therapeutics Inc | Synthesis of neurogestate |
| CN118339187A (zh) * | 2021-12-31 | 2024-07-12 | 上海宏成药业有限公司 | 抗pd-1抗体及其用途 |
| WO2023167882A1 (en) | 2022-03-01 | 2023-09-07 | Artisan Development Labs, Inc. | Composition and methods for transgene insertion |
| WO2023192895A1 (en) | 2022-03-29 | 2023-10-05 | Allogene Therapeutics Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| US20250333515A1 (en) | 2022-04-11 | 2025-10-30 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
| CN119365495A (zh) | 2022-05-27 | 2025-01-24 | 赛诺菲 | 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物 |
| CN119654406A (zh) | 2022-07-29 | 2025-03-18 | 艾洛基治疗公司 | 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞 |
| WO2024051751A1 (zh) * | 2022-09-06 | 2024-03-14 | 河北森朗生物科技有限公司 | 抗cd123的纳米抗体、嵌合抗原受体及其应用 |
| EP4590336A1 (en) * | 2022-09-20 | 2025-07-30 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted degradation and delivery of therapeutic agents |
| CN118240086B (zh) * | 2022-10-08 | 2025-05-09 | 东莞市朋志生物科技有限公司 | 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒 |
| TW202440623A (zh) | 2022-11-28 | 2024-10-16 | 美商艾洛基因醫療公司 | 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途 |
| WO2024121385A1 (en) | 2022-12-09 | 2024-06-13 | Cellectis S.A. | Two-dose regimen in immunotherapy |
| WO2024238565A1 (en) | 2023-05-15 | 2024-11-21 | Vor Biopharma Inc. | Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof |
| CN117783521B (zh) * | 2023-11-23 | 2025-03-04 | 中国农业科学院兰州兽医研究所 | 检测非洲猪瘟病毒p30蛋白抗体的竞争ELISA试剂盒 |
| CN119874909B (zh) * | 2023-12-21 | 2025-11-04 | 华润生物医药有限公司 | 抗trem2抗体及其用途 |
| WO2025233825A1 (en) * | 2024-05-06 | 2025-11-13 | Janssen Pharmaceutica Nv | Enrichment of cells expressing a bird linker |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU6704794A (en) | 1993-04-13 | 1994-11-08 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US6642043B1 (en) | 1996-03-12 | 2003-11-04 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2001243288B2 (en) | 2000-02-24 | 2005-11-24 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7517948B2 (en) | 2000-09-13 | 2009-04-14 | Multimmune Gmbh | Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| SI1578446T1 (sl) | 2002-11-07 | 2015-07-31 | Immunogen, Inc. | Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega |
| WO2004056312A2 (en) * | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| WO2004083379A2 (en) | 2003-03-14 | 2004-09-30 | Walters Richard E | Large volume ex vivo electroporation method |
| NZ543635A (en) | 2003-06-25 | 2008-05-30 | Crucell Holland Bv | Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| CA2536238C (en) | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2005054295A2 (en) | 2003-12-05 | 2005-06-16 | Multimmune Gmbh | Therapeutic and diagnostic anti-hsp 70 antibodies |
| AU2005212830B2 (en) * | 2004-02-16 | 2011-06-02 | Amgen Research (Munich) Gmbh | Less immunogenic binding molecules |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| GB0505971D0 (en) | 2005-03-23 | 2005-04-27 | Isis Innovation | Delivery of molecules to a lipid bilayer |
| RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
| JP2009508517A (ja) * | 2005-09-22 | 2009-03-05 | コーエン，イルン，アール | Ｔ細胞受容体定常ドメインの免疫原性断片及びそれに由来するペプチド |
| US20100196203A1 (en) | 2007-02-20 | 2010-08-05 | Gurdial Singh Sanghera | Formation of Lipid Bilayers |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| US8536310B2 (en) * | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| JP2012501180A (ja) | 2008-08-26 | 2012-01-19 | シティ・オブ・ホープ | Ｔ細胞の抗腫瘍エフェクター機能増進のための方法および組成物 |
| DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| EP2332994A1 (en) | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| WO2011082400A2 (en) * | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| PT3012268T (pt) | 2010-09-08 | 2018-01-31 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Recetores de antigénio quimérico com uma região de charneira otimizada |
| EP2614151B1 (en) | 2010-09-08 | 2019-07-24 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| PL3260132T3 (pl) * | 2010-10-27 | 2022-08-08 | Takeda Pharmaceutical Company Limited | Peptydy fviii do wywoływania tolerancji immunologicznej oraz immunodiagnostyki |
| WO2012058458A2 (en) | 2010-10-27 | 2012-05-03 | Cellectis Sa | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| US9040669B2 (en) | 2011-02-11 | 2015-05-26 | Memorial Sloan Kettering Cancer Center | HLA-restricted, peptide-specific antigen binding proteins |
| US8968539B2 (en) | 2011-03-08 | 2015-03-03 | Electronic Biosciences, Inc. | Methods for voltage-induced protein incorporation into planar lipid bilayers |
| BR112013024395B1 (pt) * | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
| WO2012134975A1 (en) | 2011-03-28 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
| EP3320910A1 (en) | 2011-04-05 | 2018-05-16 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| PT3459560T (pt) | 2011-04-08 | 2021-05-24 | Us Health | Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro |
| US9285592B2 (en) | 2011-08-18 | 2016-03-15 | Google Inc. | Wearable device with input and output structures |
| AU2012308205A1 (en) | 2011-09-16 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
| KR101956751B1 (ko) | 2011-10-07 | 2019-03-11 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 키메라 항원 수용체 |
| CN114634572A (zh) * | 2011-10-10 | 2022-06-17 | 希望之城公司 | 中间位和中间位结合抗体及其用途 |
| RU2644243C2 (ru) | 2011-10-20 | 2018-02-08 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы к cd22 |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| US9585969B2 (en) * | 2011-11-15 | 2017-03-07 | The Walter And Eliza Hall Institute Of Medical Research | Soluble mediator |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| EP2817331B1 (en) | 2012-02-22 | 2023-08-30 | The Trustees of the University of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
| SG11201404285VA (en) * | 2012-02-22 | 2014-10-30 | Univ Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| SG11201404769UA (en) | 2012-02-22 | 2014-11-27 | Univ Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| EP2836239A1 (en) | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| EP2855666B1 (en) | 2012-05-25 | 2019-12-04 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| EP2872218A4 (en) | 2012-07-13 | 2016-07-06 | Univ Pennsylvania | COMPOSITIONS AND METHOD FOR REGULATING HAIR GROWTH |
| AU2013312838B2 (en) * | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP2958942B1 (en) * | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| SG11201506974XA (en) | 2013-03-14 | 2015-10-29 | Bellicum Pharmaceuticals Inc | Methods for controlling t cell proliferation |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| AU2014240083C1 (en) | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| SG11201508805UA (en) | 2013-05-13 | 2015-11-27 | Cellectis | Cd19 specific chimeric antigen receptor and uses thereof |
| JP2016524464A (ja) | 2013-05-13 | 2016-08-18 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のために高活性ｔ細胞を操作するための方法 |
| JP6608807B2 (ja) * | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| KR20210115051A (ko) * | 2013-06-10 | 2021-09-24 | 다나-파버 캔서 인스티튜트 인크. | 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물 |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| EP3071221A1 (en) | 2013-11-21 | 2016-09-28 | UCL Business Plc. | Cell |
| MX378635B (es) | 2013-11-22 | 2025-03-10 | Cellectis | Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia. |
| JP2017504601A (ja) | 2013-12-20 | 2017-02-09 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 |
| CA2933707A1 (en) * | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
| CN106132423B (zh) | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| KR102157924B1 (ko) | 2014-02-14 | 2020-10-26 | 셀렉티스 | 면역 세포들 및 병리 세포들 둘 다에 존재하는 항원을 타겟팅하기 위하여 조작된 면역치료용 세포들 |
| RU2752933C2 (ru) | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| MX370272B (es) * | 2014-03-19 | 2019-12-09 | Cellectis | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. |
| CA2945620C (en) * | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| EP3171882A1 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using a cll-1 chimeric antigen receptor |
| US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| JP7098325B2 (ja) | 2014-12-05 | 2022-07-11 | シティ・オブ・ホープ | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| SG11201707089WA (en) | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| US9668192B2 (en) | 2015-10-12 | 2017-05-30 | Telefonaktiebolaget Lm Ericsson (Publ) | Cell boundary crossing in a unidirectional SFN for high speed trains |
-
2016
- 2016-01-25 CA CA2973529A patent/CA2973529A1/en not_active Abandoned
- 2016-01-25 CN CN201680006972.9A patent/CN107406516B/zh active Active
- 2016-01-25 EP EP16701616.1A patent/EP3250602A1/en not_active Withdrawn
- 2016-01-25 MX MX2017009181A patent/MX381908B/es unknown
- 2016-01-25 AU AU2016212160A patent/AU2016212160B2/en active Active
- 2016-01-25 KR KR1020177023078A patent/KR20170135824A/ko not_active Withdrawn
- 2016-01-25 CA CA2973532A patent/CA2973532A1/en not_active Abandoned
- 2016-01-25 CN CN202111329158.XA patent/CN113968915A/zh active Pending
- 2016-01-25 KR KR1020177023447A patent/KR102661969B1/ko active Active
- 2016-01-25 AU AU2016212158A patent/AU2016212158B2/en active Active
- 2016-01-25 MX MX2017009349A patent/MX2017009349A/es unknown
- 2016-01-25 CN CN201680006992.6A patent/CN107531801B/zh active Active
- 2016-01-25 AU AU2016212161A patent/AU2016212161A1/en not_active Abandoned
- 2016-01-25 ES ES16703448T patent/ES2869972T3/es active Active
- 2016-01-25 CA CA2973525A patent/CA2973525C/en active Active
- 2016-01-25 WO PCT/EP2016/051467 patent/WO2016120216A1/en not_active Ceased
- 2016-01-25 JP JP2017557487A patent/JP6884709B2/ja active Active
- 2016-01-25 AU AU2016212159A patent/AU2016212159A1/en not_active Abandoned
- 2016-01-25 US US15/546,619 patent/US20180002427A1/en not_active Abandoned
- 2016-01-25 JP JP2017557490A patent/JP2018504144A/ja not_active Withdrawn
- 2016-01-25 EP EP16703448.7A patent/EP3250604B1/en active Active
- 2016-01-25 US US15/546,633 patent/US11014989B2/en active Active
- 2016-01-25 DK DK16703448.7T patent/DK3250604T3/da active
- 2016-01-25 WO PCT/EP2016/051471 patent/WO2016120220A1/en not_active Ceased
- 2016-01-25 MX MX2017009182A patent/MX389057B/es unknown
- 2016-01-25 EP EP16704136.7A patent/EP3250607A1/en not_active Withdrawn
- 2016-01-25 WO PCT/EP2016/051469 patent/WO2016120218A1/en not_active Ceased
- 2016-01-25 CA CA2973524A patent/CA2973524A1/en not_active Abandoned
- 2016-01-25 ES ES16703450T patent/ES2842212T3/es active Active
- 2016-01-25 WO PCT/EP2016/051470 patent/WO2016120219A1/en not_active Ceased
- 2016-01-25 CN CN202111328553.6A patent/CN113968914A/zh active Pending
- 2016-01-25 JP JP2017557489A patent/JP6779909B2/ja active Active
- 2016-01-25 RU RU2017129591A patent/RU2732925C2/ru active
- 2016-01-25 DK DK16703450.3T patent/DK3250606T3/da active
- 2016-01-25 US US15/546,604 patent/US20180000914A1/en not_active Abandoned
- 2016-01-25 AU AU2016212162A patent/AU2016212162A1/en not_active Abandoned
- 2016-01-25 RU RU2017129455A patent/RU2017129455A/ru not_active Application Discontinuation
- 2016-01-25 JP JP2017557488A patent/JP2018504143A/ja active Pending
- 2016-01-25 JP JP2017557491A patent/JP2018504145A/ja active Pending
- 2016-01-25 US US15/546,630 patent/US20180002435A1/en not_active Abandoned
- 2016-01-25 WO PCT/EP2016/051468 patent/WO2016120217A1/en not_active Ceased
- 2016-01-25 RU RU2017129592A patent/RU2731543C2/ru active
- 2016-01-25 US US15/546,623 patent/US20180051089A1/en not_active Abandoned
- 2016-01-25 KR KR1020177021615A patent/KR102329836B1/ko active Active
- 2016-01-25 BR BR112017015453-6A patent/BR112017015453A2/pt not_active Application Discontinuation
- 2016-01-25 BR BR112017013981-2A patent/BR112017013981A2/pt active Search and Examination
- 2016-01-25 EP EP16703449.5A patent/EP3250605A1/en not_active Ceased
- 2016-01-25 EP EP16703450.3A patent/EP3250606B1/en active Active
- 2016-01-25 CN CN201680006922.0A patent/CN107438618A/zh active Pending
-
2017
- 2017-06-15 IL IL252937A patent/IL252937B/en unknown
- 2017-06-19 IL IL253012A patent/IL253012A0/en unknown
- 2017-06-20 IL IL253049A patent/IL253049B/en unknown
-
2023
- 2023-10-05 US US18/481,797 patent/US20240228636A1/en active Pending